In vitro evaluation and characterization of newly designed alkylamidophospholipid analogues as anti-human immunodeficiency virus type 1 agents

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 2, 1998, Pages 157-165

  Kucera, L S ^a   Iyer, N ^a   Morris Natschke, S L ^b   Chen, S Y ^b   Gumus, F ^c   Ishaq, K ^b   Herrmann, D B J ^d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c GAZI UNIVERSITY   (Turkey)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

AIDS; Alkylamidophosphocholine; HIV 1; Phospholipid nucleoside conjugate

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NUCLEOSIDE DERIVATIVE; PHOSPHORYLCHOLINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW CELL; DRUG POTENCY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

EID: 0031922368     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029800900207     Document Type: Article

References (19)

1. Chou T-C & Talalay P (1987) Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In New Avenues in Developmental Cancer Chemotherapy, vol. 8, pp. 37-64. Bristol-Myers Cancer Symposia. Edited by K Harrap & T Connors. New York: Academic Press.
2. De Clercq E (1995) Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. Journal of Medicinal Chemistry 38:2491-2517.
3. Feng Y, Broder CC, Kennedy E & Berger EA (1997) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
4. Hansen BD, Nara PL, Maheshwari RK, Sidhu GS, Bernbaum JG, Hoekzema D, Meltzer MS & Gendelman HE (1992) Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120. Journal of Virology 66:7543-7548.
5. Hansen WJ, Murari R, Wedmid Y & Baumann WJ (1982) An improved procedure for the synthesis of choline phospholipids via 2-bromoethyl dichlorophosphate. Lipids 17:453-459.
6. Johnson VA, Walker BD, Barlow MA, Paradsi TJ, Chou T-C & Hirsch MS (1989) Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3′-azido-3′-deoxythymidine. Antimicrobial Agents and Chemotherapy 33:53-57.
7. Krugner-Higby L, Goff D, Edwards T, Iyer N, Neufeld J, Kute T, Morris-Natschke S, Ishaq K, Piantadosi C & Kucera LS (1995). Membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gpl60/gp120 binding to monoclonal antibody. AIDS Research and Human Retroviruses 11:705-712.
8. Kucera LS, Iyer N, Leake E, Raben A, Modest EJ, Daniel LW & Piantadosi C (1990a) Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation. AIDS Research and Human Retroviruses 6:491-501.
9. Kucera LS, Iyer N, Leake E, Raben A, Daniel L, Modest EJ & Piantadosi C (1990b) Effect of membrane-active ether lipid (EL) analogs on human immunodeficiency virus production measured by plaque assay. Annals of the New York Academy of Sciences 616:545-548.
10. McKnight A, Wilkinson D, Simmons G, Talbot S, Picard L, Ahuja M, March M, Hoxie JA & Clapham PR (1997) Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a co-receptor (CXCR4) is both cell type and virus strain dependent. Journal of Virology 71:1692-1696.
11. Meyer KL, Marasco CJ Jr, Morris-Natschke SL, Ishaq KS & Piantadosi C (1991) In vitro evaluation of phosphocholine and quaternary ammonium containing lipids as novel anti-HIV agents. Journal of Medicinal Chemistry 34:1377-1383.
12. Morris-Natschke SL, Gumus F, Marasco CJ Jr, Meyer KL, Marx M, Piantadosi C, Layne MD & Modest EJ (1993) Synthesis of phosphocholine and quaternary amine ether lipids and evaluation of in vitro antineoplastic activity. Journal of Medicinal Chemistry 36:2018-2025.
13. Piantadosi C, Marasco CJ Jr, Morris-Natschke SL, Meyer KL, Gümüs F, Surles JR, Ishaq KS, Kucera LS, Iyer N, Wallen CA, Piantadosi S & Modest EJ (1991) Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity. Journal of Medicinal Chemistry 34:1408-1414.
14. Ryu EK & MacCoss M (1979) Modification of the Dittmer-Lester reagent for the detection of phospholipid derivatives on thin-layer chromatogrzms. Journal of Lipid Research 20:561-563.
15. Smith MS, Thresher RJ & Pagano JS (1991) Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon. Antimicrobial Agents & Chemotherapy 35:62-67.
16. Storme GA, Berdel WE, van Blitterswijk WJ, Bruyneel EA, DeBruyne GK & Mareel MM (1985) Anti-invasive effect of racemic 1-O-octadecyl-2-0-methylglycero-3-phosphocholine on M04 mouse fibrosarcoma cells in-vitro. Cancer Research 45:351-357.
17. van Blitterswijk WJ, Hilkmann H & Storme GA (1987) Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion. Lipids 22:820-823.
18. White EL, Buckheit RW Jr, Ross IJ, Germany JM, Andries K, Pauwels R, Janssen PAJ, Shannon WM and Chirigos MA (1991) ATIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Research 16:257-266.
19. Willey RL, Bonifacino JS, Potts BJ, Martin MA & Klausner RD (1988) Biogenesis, cleavage, and degradation of the human immunodeficiency virus type 1 envelope glycoprotein gp160. Proceedings of the National Academy of Sciences, USA 85:9580-9584.